ZBIOZenas BioPharma, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but heavy debt (CCC) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -75% · now 37% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ZBIO take a bad year?
The deepest fall in ZBIO's price history on file is −75%; it is 37% below its high today.
Altman Z-score · distress below 1.8 · safe above 3 · distress zone, the model puts this in the bankruptcy range
- Cash runway
- 2.9 years
Cash runway · burning $56M a quarter at the current rate
- Annualised volatility
- 104%
Annualised volatility · three times the market's own swing
- Worst drawdown on file
- −75%
Worst drawdown on file · −37% today
Details›
- Cash and short-term investments
- $643M
- EBITDA, trailing twelve months
- −$476M
- Operating profit, trailing twelve months
- −$476M
- Annualised volatilitytwo years of daily moves
- 104%
- Worst drawdown on file
- −75%
- Below its 52-week high
- 37%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry